Humalog kwikpen and Drowsiness - a phase IV clinical study of FDA data

Summary:

Drowsiness is reported as a side effect among people who take Humalog kwikpen (insulin lispro recombinant), especially for people who are female, 50-59 old, also take Humalog, and have Breast cancer female.

The phase IV clinical study analyzes which people have Drowsiness when taking Humalog kwikpen. It is created by eHealthMe based on reports of 3,425 people who have side effects when taking Humalog kwikpen from the FDA, and is updated regularly.

What is Humalog kwikpen?

Humalog kwikpen has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 3,512 Humalog kwikpen users. Check the latest studies of Humalog kwikpen.

What is Drowsiness?

Drowsiness is found to be associated with 2,865 drugs and 4,797 conditions by eHealthMe. Check the latest studies of Drowsiness.

On Apr, 18, 2026

3,425 people reported to have side effects when taking Humalog kwikpen.
Among them, 20 people (0.58%) have Drowsiness.

Among these 20 people:

What is the gender of people who have Drowsiness when taking Humalog kwikpen? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Drowsiness when taking Humalog kwikpen? *

What are other drugs people take besides Humalog kwikpen? *

What are other side effects people have besides Drowsiness? *

Blood Glucose Increased: 10 people, 50.00%
Fatigue (feeling of tiredness): 6 people, 30.00%
Headache (pain in head): 3 people, 15.00%
Blood Glucose Decreased: 3 people, 15.00%
Glycosylated Haemoglobin Increased: 3 people, 15.00%
Dyspnea (difficult or laboured breathing): 3 people, 15.00%
Irritability: 3 people, 15.00%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 15.00%
Feeling Abnormal: 2 people, 10.00%
Hypoglycemia (low blood sugar): 2 people, 10.00%

What are the existing conditions these people have? *

Tardive Dyskinesia (a disorder that involves involuntary movements): 1 person, 5.00%
Renal Cell Carcinoma (a kidney cancer): 1 person, 5.00%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 5.00%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 5.00%
Lung Disorder (lung disease): 1 person, 5.00%
High Blood Cholesterol: 1 person, 5.00%
Eye Disorder: 1 person, 5.00%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 1 person, 5.00%
Breast Cancer Female: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Humalog kwikpen and have Drowsiness?

- Check whether Drowsiness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Humalog kwikpen:

Humalog kwikpen (3,512 reports)

Drowsiness treatments and more:

Drowsiness (269,040 reports)

Browse all side effects of Humalog kwikpen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Drowsiness:

Drowsiness (2,865 drugs)

Browse all the conditions that are associated with Drowsiness:

Drowsiness (4,797 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin lispro recombinant (the active ingredients of Humalog kwikpen) and Humalog kwikpen (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.